WS Investor
30 Mar 2026, 20:01
Blackstone Inc. announced the final close of its latest life sciences fund, raising a record $6.3 billion.
The fund, Blackstone Life Sciences VI (BXLS VI), was oversubscribed and is the largest private fund dedicated to life sciences, approximately 40% larger than its predecessor.
The strategy focuses on financing the development and commercialization of innovative medicines and medical technologies, leveraging Blackstone’s partnerships and track record, including multiple regulatory approvals across pharmaceuticals and devices.
The announcement highlights strong investor demand for healthcare and biotech investments, as well as Blackstone’s growing role as a major capital provider in advancing new therapies globally.
The fund, Blackstone Life Sciences VI (BXLS VI), was oversubscribed and is the largest private fund dedicated to life sciences, approximately 40% larger than its predecessor.
The strategy focuses on financing the development and commercialization of innovative medicines and medical technologies, leveraging Blackstone’s partnerships and track record, including multiple regulatory approvals across pharmaceuticals and devices.
The announcement highlights strong investor demand for healthcare and biotech investments, as well as Blackstone’s growing role as a major capital provider in advancing new therapies globally.
